Correction: Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial

• D. Molina-Morant,
• M. L. Fernández,
• P. Bosch-Nicolau,
• E. Sulleiro,
• M. Bangher,
• F. Salvador,
• A. Sanchez-Montalva,
• A. L. P. Ribeiro,
• A. M. B. de Paula,
• S. Eloi,
• R. Correa-Oliveira,
• J. C. Villar,
• S. Sosa-Estani,
• I. Molina

Affiliations

D. Molina-Morant

Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona

M. L. Fernández

Departamento de Clínica, Patología y Tratamiento, Instituto Nacional de Parasitología Dr. Mario Fatala Chaben, Ministerio de Salud y Desarrollo Social

P. Bosch-Nicolau

Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona

E. Sulleiro

Microbiology Department, Vall d’Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona

M. Bangher

Instituto de Cardiología de Corrientes Juana Francisca Cabral (Argentina)

F. Salvador

Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona

A. Sanchez-Montalva

Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona

A. L. P. Ribeiro

Programa de Pós-Graduação Infectologia E Medicina Tropical, Faculdade de Medicina da Universidade Federal de Minas Gerais

A. M. B. de Paula

Laboratory of Health Science, Postgraduate Program in Health Sciences, Universidade Estadual de Montes Claros (Unimontes)

S. Eloi

Programa de Pós-Graduação Em Patologia, Departamento de Propedêutica Complementar, Faculdade de Medicina da Universidade Federal de Minas Gerais

R. Correa-Oliveira

René Rachou Institute, Oswaldo Cruz Foundation

J. C. Villar

Faculty of Health Sciences, Universidad Autónoma de Bucaramanga and Research Department

S. Sosa-Estani

Chagas Clinical Program, Drugs for Neglected Disease Initiative (DNDi)

I. Molina

Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona